HCW Biologics Regains Nasdaq Compliance with One-for-Six Reverse Split through June 2027
HCWB•On June 29, 2026, HCW Biologics regained compliance with Nasdaq Listing Rule 5550(a)(2) after implementing a one-for-six reverse stock split on June 30, 2026. The company is subject to a mandatory monitoring period ending June 17, 2027.
1. Nasdaq Compliance Regained
On June 29, 2026, the Nasdaq Hearings Panel concluded that HCW Biologics met the requirements of Listing Rule 5550(a)(2) by restoring its bid price above the minimum threshold. This decision lifts the company’s deficiency status and allows continued trading under standard listing conditions.
2. Reverse Split and Monitoring Period
To secure long-term compliance, HCW Biologics executed a one-for-six reverse stock split on June 30, 2026. The company will remain under a mandatory monitoring period through June 17, 2027, during which it must maintain the required bid price to avoid delisting.
